

SEARCH...

[HOME](#) [ABOUT US](#) [TECHNOLOGY](#) [PEOPLE](#) [NEWS & PUBLICATIONS](#) [LINKS](#)

## PRESS RELEASES

A list of the most recent press releases issued by TREVENTIS Corporation are shown below. If you click on any listing, it will open to display the full text of the release. (Click again to close).

### NEWS & PUBLICATIONS

[PRESS RELEASES](#)[PUBLICATIONS](#)

[DECEMBER 16, 2009 – Treventis Scientific Founder Donald Weaver, MD, Named 2009 Recipient of Prix Galien Canada Award for Outstanding Achievement in Development of New Medicines for Alzheimer's Disease](#)

**Treventis Scientific Founder Donald Weaver, MD, Named 2009 Recipient of Prix Galien Canada Award for Outstanding Achievement in Development of New Medicines for Alzheimer's Disease**

**Dr. Weaver honored for advances in development of new therapies to treat chronic neurological disorders**

December 16, 2009 – Philadelphia, PA – Treventis Corporation announced today that the company's scientific founder, Donald F. Weaver, MD, PhD, is the recipient of the 2009 Prix Galien Research Award for his groundbreaking efforts to design novel drug therapies to treat chronic neurological disorders such as Alzheimer's disease. The Prix Galien Award is presented each year to honor outstanding achievements in the development of new medicines. Alzheimer's disease is characterized by reduction of memory and cognitive skills through loss of or impaired function of synaptic connections in the brain. Dr. Weaver has worked to advance a research platform to develop therapeutic options focused on cellular pathways and targets that, if modulated, may halt disease progression or improve cognitive function.

"We are very pleased that Dr. Weaver's important research has been recognized with this prestigious honor. His work has provided essential support and scientific knowledge to advance the innovative approach that TREVENTIS employs in developing novel disease-modifying compounds," said William McIntosh, Chairman and CEO, TREVENTIS Corp.

The proprietary discovery technology at TREVENTIS targets protein misfolding to inhibit the aggregation of amyloid proteins, including beta-amyloid (plaque) and tau proteins (tangles), both associated with the neuronal loss in AD. This proprietary discovery platform is a high-resolution three-dimensional (3D) "in silico" (computer-based) model of the Common Conformational Region, enabling rational design of multiple lead compounds.

Dr. Weaver, a board certified neurologist and renowned medicinal chemist, said, "I'm deeply honored to receive this prestigious award and to be involved in efforts to advance important research could have a profoundly positive impact on efforts to treat people with chronic neurological diseases."

**About TREVENTIS Corporation**

TREVENTIS is headquartered in Southeastern Pennsylvania and has research operations in Halifax, Nova Scotia, Canada. The company is focused on the discovery and early stage development of disease-modifying small molecule drugs for Alzheimer's and other protein misfolding diseases such as Parkinson's and Huntington's diseases. In addition to its therapeutic programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring treatment effects in Alzheimer's disease, MS and primary brain tumors.

For more information contact:

L. William McIntosh, CEO  
TREVENTIS Corporation  
www.TREVENTIS.com  
mcamci@msn.com and  
wmcintosh@treventis.com  
610-488-6081

---

---

copyright © 2013 TREVENTIS Corporation